Navigation Links
Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia
Date:6/17/2009

OSLO, Norway, June 17 /PRNewswire-FirstCall/ --

- New Investigational Drug Also Shown to Improve Remission Rates and Reduce Short-Term Mortality Compared to Previous Treatments

Clavis Pharma ASA (OSE: CLAVIS) today announces positive final results from a Phase II trial of its novel investigational cancer drug, elacytarabine (CP-4055), in patients with late-stage acute myeloid leukaemia (AML). In the trial, elacytarabine showed statistically significant superior efficacy compared to published clinical data for late-stage AML. Based on these encouraging results an elacytarabine registration study is being planned.

    Key results compared to published clinical data:

    - Median survival three times longer (5.5 months vs. 1.5 months)
    - Remission rate significantly increased (15% vs 2.5%, p<0.0001)
    - Well tolerated - short-term mortality substantially lower (13 per
      cent vs. 25 per cent)

Elacytarabine is a novel cytotoxic agent being developed by Clavis Pharma for the treatment of hematologic cancers and solid tumors, especially those resistant to existing agents. One particularly difficult-to-treat patient group is late-stage acute myeloid leukaemia (AML) patients who have failed two previous therapeutic regimens. There is currently no standard therapy available for these patients and life expectancy is very short. It is in this patient group that Clavis Pharma has evaluated the safety and efficacy of elacytarabine.

Extended survival, improved remissions

In the Phase II study, 61 patients with late stage AML who failed to respond or relapsed after two separate rounds of treatments received third-line therapy (also called second salvage) with intravenous elacytarabine. The response to treatment was compared with a detailed historical outcome analysis of 594 similar second salvage AML patients, who were treated at the MD Anderson C
'/>"/>

SOURCE Clavis Pharma ASA
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Delaware , June 18, 2013 ... announce the release of the HELM biomolecular representation ... open source MIT licence. HELM (Hierarchical ... a wide range of biomolecules (e.g. proteins, nucleotides, ... existing small-molecule and sequence-based informatics methodologies impractical or ...
(Date:6/18/2013)... June 18, 2013 The "Bioinformatics Market By ... Knowledge Management Tools & Data Analysis Services) & Application (Genomics, ... the Major Market Drivers, Restraints, and Opportunities in ... Asia-Pacific and Rest of World. ... 22 Figures 364 ...
(Date:6/18/2013)... , June 18, 2013 ... has announced the addition of the report ... Companies " to their offering. ... briefly reviews basics of human genome variations, ... Current large and small sequencers are described ...
(Date:6/18/2013)... , June 18, 2013 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/cmbgcv/north_american ) has announced the ... Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market ... Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] ... 2017" report to their offering. ...
Breaking Biology Technology:The Pistoia Alliance Releases HELM Biomolecular Representation Standard Open Source Tools 2Bioinformatics Market Worth $7.5 Billion by 2017 2Bioinformatics Market Worth $7.5 Billion by 2017 3DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 2North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 3
... Flexibility and Transmission and ... Induction Functionality --, Medical Design & Manufacturing East DRC,s Metrigraphics Division ... ... Dynamics Research,Corporation,s Metrigraphics Division (Nasdaq: DRCO ), a world-leading,precision manufacturer specializing ...
... 3 BioStorage Technologies, Inc.,(BST), today announced the ... board consists of four life science industry leaders ... and expertise in their,respective fields of study. The ... for the ongoing development of the company,s,services, as ...
... -- Microscopic robots crafted to maneuver separately without any ... years of continuing research led by a Duke University ... do assembly and control at this fine a resolution ... a Duke professor of computer science and biochemistry. , ...
Cached Biology Technology:DRC's Metrigraphics Announces Family of Micro-Induction Coils for Implanted and Traditional Medical Applications 2DRC's Metrigraphics Announces Family of Micro-Induction Coils for Implanted and Traditional Medical Applications 3DRC's Metrigraphics Announces Family of Micro-Induction Coils for Implanted and Traditional Medical Applications 4BioStorage Technologies Forms Scientific Advisory Board with Leading Life Science Experts 2Microrobots dance on something smaller than a pin's head 2Microrobots dance on something smaller than a pin's head 3
(Date:6/17/2013)... understand the concept of improving original foundations with more ... the University of Pittsburgh,s Kenneth P. Dietrich School of ... that could make drug delivery, gas storage, and gas ... findings were reported in the latest issue of the ... JACS ). , The recent work builds upon Pitt ...
(Date:6/17/2013)... Kansas State University research associate has received a prestigious ... to prevent the spread of malaria. , Bart Bryant, ... of Health,s National Research Service Award Individual Postdoctoral Fellowship, ... seventh Kansas State University researcher to receive the award ... hold such an award. , Bryant, a university doctoral ...
(Date:6/17/2013)... the controversial method of mining shale gas, is widespread ... Appalachian Basin. New research in the Annals of ... threat posed to biodiversity including pollution from toxic chemicals, ... to wetlands. , "Shale gas has engendered a great ... human health, but effects on biological diversity and resources ...
Breaking Biology News(10 mins):'Chemical architects' build materials with potential applications in drug delivery and gas storage 2NIH fellowship helps researcher fight malaria, understand mosquito immunity 2
... more consistent and predictable fisheries but do not necessarily ... online this week by the journal Proceedings of the ... around the world, catch shares a management system ... the total allowable catch to individual fishermen or fishing ...
... NY) Researchers at the Albert Einstein College of ... for treating and healing skin abscesses caused by bacteria ... journal PLoS One. Abscesses are deep skin infections ... For their new treatment strategy, the Einstein scientists developed ...
... 22, 2009Global warming, pollution, and the environmental consequences of ... communities, and strategies to prevent these inequities are urgently ... presents the global implications of climate change and its ... special issue of Environmental Justice , a peer-reviewed ...
Cached Biology News:New study finds catch shares improve consistency, not health, of fisheries 2Novel nanotechnology heals abscesses caused by resistant staph bacteria 2Novel nanotechnology heals abscesses caused by resistant staph bacteria 3Disproportionate effects of global warming and pollution on disadvantaged communities 2
... Thermo's Wellwash AC is the ... available, and is provided with liquid ... rinse bottles. The integrated orbital shaker ... guarantee excellent washing performance. The big ...
The Wellwash 4 Mk 2 microplate washer combines flexibility, simplicity and ease of use. This reliable microplate washer meets the exacting standards of today's ELISA assay requirements....
... a genetically engineered endonuclease. This unique enzyme ... while having no proteolytic activity. It is ... and possesses an exceptionally high specific activity. ... recombinant proteins, its use enables compliance with ...
... genome-wide microRNA expression profiling and built ... microfluidic on-chip synthesis platform. These microarrays ... comprehensive microRNA Expression Profiling Service. ... microRNA Microarray contains all known rice ...
Biology Products: